Role of Liquid Chlorophyll As Adjuvant Therapy In Children With Beta Thalassemia
Phase 3
Not yet recruiting
- Conditions
- Haematological DisordersPaediatrics
- Registration Number
- PACTR202404706815223
- Lead Sponsor
- Faculty of Medicine Tanta University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Children with ß- thalassemia aged 1 -18 years
Exclusion Criteria
1.Children with ß- thalassemia who are not compliant with liquid chlorophyll therapy.
2.Children with ß- thalassemia who are allergic to liquid chlorophyll.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link liquid chlorophyll to improved erythropoiesis in beta thalassemia patients?
How does liquid chlorophyll adjuvant therapy compare to standard iron chelation in pediatric beta thalassemia management?
Which biomarkers correlate with response to chlorophyll supplementation in beta-globin gene mutation subtypes?
What adverse events are associated with liquid chlorophyll in children with beta thalassemia and how are they managed?
Are there synergistic effects of chlorophyll with hydroxyurea or other hematopoietic agents in thalassemia treatment?